

**FAX**

To Examiner Richard Raymond, Group Art U: 1624

Type site code here

Company USPTO

Fax 571 273-0673

From Lorie Ann Morgan

Tel / Fax 919 483-8222 / 919 483-7977

E-mail [Lorie.A.Morgan@gsk.com](mailto:Lorie.A.Morgan@gsk.com)

Date 21-Oct-2004 Pages including cover 6

Subject USSN 10/089,964

**Serial No. 10/089,964**  
**Filing Date: 8 May 2002**  
**Applicant: Alvaro et al.**  
**Title: Chemical Compounds**

**Attached:** Copy of IDS and PTO-1449 filed 18 May 2004 and confirmation of receipt by PTO.

Dear Ex. Raymond,

Attached for your consideration is a copy of the IDS and PTO-1449 filed 18 May 2004 together with confirmation of receipt by the PTO. Kindly consider the reference identified on the PTO-1449 in connection with the above-referenced patent application and return an initialed copy of the PTO-1449 at your earliest convenience. I would be grateful to receive the initialed PTO-1449 before the due date for filing the issue fee.

Applicants also respectfully request favorable consideration of the Petition to Change Inventorship, filed on 15 June 2004.

Thank you for your assistance in this case and please do not hesitate to contact me should you require anything further.

Sincerely,

Lorie Ann Morgan  
Reg. No. 38,181  
Attorney for Applicants

GlaxoSmithKline  
phone: 919 483-8222  
fax: 919 483-7977

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

**FAX****GlaxoSmithKline****To** Attn: Group Art Unit 1624**Company** USPTO**Fax** 703-872-9306**From** Valerie L. Phillips**Tel** 919-483-8223 **Fax** 919-483-5730**E-mail** [Vlp47157@gsk.com](mailto:Vlp47157@gsk.com)**Date** May 18, 2004 **Pages including cover** 18**Subject** Supplemental IDS

Glaxo Wellcome Inc.  
PO Box 13388  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

**Serial No.:** 10/089,964  
**Filing Date:** May 8, 2002  
**Applicant:** Alvaro et al.  
**Title:** Chemical Compounds

Attached:  
Transmittal Form w/Certificate of transmission via facsimile  
Supplemental IDS  
PTO1449  
1 Reference

Thank you,  
Valerie Phillips

**Certificate of Transmission by Facsimile (37 CFR 1.8)**

I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on May 18, 2004.

A handwritten signature in cursive script, reading "Valerie L. Phillips", written over a horizontal line.  
Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PI3806USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alvaro et al.

Serial No.: 10/089,964

Group Art Unit: 1624

File Date: May 8, 2002

Examiner: R. Raymond

For: Chemical Compounds

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed:  
☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))  
☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
  - (2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No. \_\_\_\_\_

In accordance with the requirements of 37 CFR 1.97(d):

PI3806USW

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan  
Registration No. 38,181

Date: 5/18/04  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8222  
Facsimile: (919) 483-7988

## Auto-Reply Facsimile Transmission



TO: Fax Sender at 919 483 5730

Fax Information  
 Date Received: 5/18/2004 10:21:55 AM [Eastern Daylight Time]  
 Total Pages: 18 (including cover page)

**ADVISORY:** This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received  
 Cover  
 Page  
 =====>

FAX		gsk GlaxoSmithKline	
To:	Alm: Group Adm 1524	GlaxoSmithKline Inc. PO Box 10000 Research Triangle Park North Carolina 27709 Tel: 919 483 2100 www.gsk.com	
Company:	USPTO		
Fax:	703-672-8306		
From:	Valerie L. Phillips		
Tel:	919-483-8223 Fax: 919-483-5730		
E-mail:	VLP47187@uspto.gov		
Date:	May 18, 2004	Pages including cover:	18
Subject:	Supplemental IDS		
<p>Serial No.: 10089884                  Filing Date: May 8, 2002                  Applicant: Alvaro et al.                  Title: Chemical Compounds</p> <p>Attached:                  Transmittal Form w/ Certificate of Transmission via facsimile                  Supplemental IDS                  PTO1448                  1 Reference</p> <p>Thank you,                  Valerie Phillips</p> <p><u>Certificate of Transmission by Facsimile (37 CFR 1.8)</u>                  I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-672-8306) on May 18, 2004.</p> <p><i>Valerie L. Phillips</i>                  Valerie L. Phillips</p> <p><small>The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the addressee, or if you are responsible to do so, please do not disseminate, copy, or otherwise use this information in any way. If you have received this transmission in error, please contact the sender immediately by telephone so that we can arrange for its return.</small></p>			
PAGE 1/18 * RCVD AT 5/18/2004 10:21:55 AM [Eastern Daylight Time] * SVR:USPTO-EPXDF-1R * DNIS:822306 * CSID:919 483 5730 * DURATION (mm:ss):02:46			

